Item 1.01 - Entry into a Material Definitive Agreement: Molina Healthcare entered into a material definitive agreement on February 4, 2026 (specific details of the agreement are not provided in the header section of this filing) Item 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement: The company created a direct financial obligation or…

Our analysis rates this filing BEARISH. Molina Healthcare faces material near-term operational challenges evidenced by the extraordinary covenant amendment just 11 weeks after credit agreement execution. The 42% reduction in required interest coverage ratio is a stark signal that the company's…

Concern level: HIGH (7.6/10). Key factors: Three new high-severity risks identified (average severity 7.7/10) with overall risk trend INCREASING; Covenant waiver within 11 weeks of credit agreement origination signals rapid operational deterioration and lender concern about debt service capacity; Interest coverage ratio slashed 42% (3.00x to 1.75x for 2026), indicating material decline in EBITDA…

Notable risk changes: Credit agreement amended within 11 weeks of origination with interest coverage ratio slashed 42% (from 3.00x to 1.75x for 2026 quarters), signaling rapid operational deterioration and lender concern about debt service capacity; $93 million intangible asset impairment charge announced for Q1 2026 due to strategic exit from Medicare Advantage Prescription Drug product, indicating prior capital…

The model predicts MOH will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.